<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00761969</url>
  </required_header>
  <id_info>
    <org_study_id>PID-PAB</org_study_id>
    <nct_id>NCT00761969</nct_id>
  </id_info>
  <brief_title>Prevention of Ischemic Events in Patients With Peripheral Arterial Disease</brief_title>
  <acronym>PID-PAB</acronym>
  <official_title>Prevention of Ischemic Events in Patients With Peripheral Arterial Disease by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KRKA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ljubljana School of Medicine, Slovenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Krka, d.d., Novo mesto, Slovenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>KRKA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PID-PAB study aims to test the efficacy of the European Guidelines on Cardiovascular
      Disease Prevention in patients with peripheral arterial disease. Survival, the rate of major
      atherothrombotic events (myocardial infarction, stroke, critical limb ischemia) and the
      incidence of revascularization procedures will be compared between a group of patients with
      stable peripheral arterial disease (PAD) and age- and sex-matched control subjects without
      PAD. Both groups will be receiving up-to-date medical care according to their cardiovascular
      risk based on the European Guidelines on Cardiovascular Disease Prevention in Clinical
      Practice. Yearly follow-up is planned for 5 years. The PID PAB study aims to test (a) whether
      stable PAD is still an adverse prognostic indicator in spite of contemporary preventive
      measures, and (b) to what extent do contemporary preventive measures improve the prognosis of
      patients with PAD in comparison to historic controls, representing the natural history of the
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The observational study Prevention of Ischemic Events in Patients with Peripheral Arterial
      Disease by the European Guidelines on Cardiovascular Disease Prevention (Slovenian acronym of
      the study: PID-PAB)aims to test the efficacy of the European Guidelines on Cardiovascular
      Disease Prevention in patients with peripheral arterial disease, who have an even higher
      mortality rate than patients with isolated coronary artery disease or cerebrovascular disease
      when left to the natural course of the disease. The PID-PAB study will compare the rates of
      survival, major atherothrombotic events (myocardial infarction, stroke, critical limb
      ischemia) and revascularization procedures between a group of patients with stable peripheral
      arterial disease (PAD) and a control group of age- and sex-matched subjects without PAD. Both
      groups will be receiving up-to-date medical care (including life-style advice and
      prescription of cardioprotective medication) according their cardiovascular risk based on the
      European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. PAB is defined
      by a reduced ankle-brachial pressure index of =&lt; 0.90, while absence of PAD is defined by
      palpable pedal pulses and a normal ankle-brachial index (0.91-1.30). Exclusion criteria are:
      age &lt; 40 or &gt; 80 years at inclusion, active cancer or other disease with a life expectancy of
      les than 5 years, any major atherothrombotic event in 30 days prior to enrollment, and
      pregnancy. All subjects will be followed annually for 5 years by comprehensive medical
      examinations. The settings of the study are primary care facilities in Slovenia, European
      Union. The target size of each group is 1000 subjects, i.e., 5000 patient years. The number
      of participating physicians-researchers is estimated at 100, with a goal for each physician
      to recruit 10 patients with PAD and 10 age- and sex-matched controls. The study is
      coordinated by a steering committee consisting of researchers from the Department of Vascular
      Diseases at the University of Ljubljana Medical Centre, Institute of Biomedical Informatics
      at the University of Ljubljana School of Medicine, Department of Family Medicine at the
      University of Ljubljana School of Medicine and the pharmaceutical company Krka, Slovenia, who
      is also the sponsor of the study. The protocol of the study has been approved by the
      Committee of Medical Ethics of the Republic of Slovenia.

      The PID PAB study aims to answer the questions:

        1. Is stable PAD is still an adverse prognostic indicator in spite of contemporary
           preventive measures?

        2. To what extent do contemporary preventive measures improve the prognosis of patients
           with PAD in comparison to historic controls (described in earlier reports on the natural
           history of PAD ? We expect to still find a significant difference in the rate of
           cardiovascular events between patients with PAD and their peers without PAD, but we
           hypothesize that contemporary preventive measures will strongly attenuate the adverse
           prognosis of PAD regarding survival and major atherothrombotic events in comparison to
           the natural history of the disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Major Cardiovascular Events</measure>
    <time_frame>5 years:</time_frame>
    <description>Total number of deaths, cardiovascular deaths, non-fatal myocardial infarctions, ischemic strokes and critical limb ischemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Revascularization Procedures</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of coronary, carotid and peripheral arterial revascularization procedures</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1455</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>PAB</arm_group_label>
    <description>Subjects with stable peripheral arterial disease; ankle-brachial pressure index on at least one leg =&lt; 0.90.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Subjects without peripheral arterial disease (palpable pedal pulses and a normal ankle-brachial pressure index of 0.91-1.30), age- and sex-matched to the stuy group with PAD</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice</intervention_name>
    <description>Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.</description>
    <arm_group_label>PAB</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood (16 ml) for analysis of inflammatory markers (from serum) and genotyping, to be
      correlated with clinical outcomes.

      Anonymity of patients is proveded by coding the samples and the patients clinical records.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stable, objectively confirmed PAD, recruited from primary care settings in
        Slovenia, Europe.

        Control subjects of comparable age- and sex-distribution, without PAD, recruited from
        primary care settings in Slovenia, Europe.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with PAD: ankle-brachial pressure index &lt;= 0.90

          2. Controls: palpable pedal pulses, ankle-brachial pressure index 0.91-1.30

        Exclusion Criteria:

          1. Age &lt; 40 or &gt; 80 years at inclusion

          2. Malignancy with a life expectancy &lt; 5 years

          3. Atherothrombotic event within a month before inclusion (acute coronary syndrome,
             stroke or documented transient ischemic attack, critical limb ischemia)

          4. pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ales Blinc, MD, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Vascular Diseases, University of Ljubljana Med Ctr</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Vascular Diseases, University of Ljubljana Medical Center</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <reference>
    <citation>Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992 Feb 6;326(6):381-6.</citation>
    <PMID>1729621</PMID>
  </reference>
  <reference>
    <citation>Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, Powe NR, Siscovick D. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):538-45.</citation>
    <PMID>10073955</PMID>
  </reference>
  <reference>
    <citation>Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001 Sep 19;286(11):1317-24.</citation>
    <PMID>11560536</PMID>
  </reference>
  <reference>
    <citation>Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71-86. Erratum in: BMJ 2002 Jan 19;324(7330):141.</citation>
    <PMID>11786451</PMID>
  </reference>
  <reference>
    <citation>Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 Jul 6;360(9326):7-22.</citation>
    <PMID>12114036</PMID>
  </reference>
  <reference>
    <citation>Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145-53. Erratum in: 2000 May 4;342(18):1376. N Engl J Med 2000 Mar 9;342(10):748.</citation>
    <PMID>10639539</PMID>
  </reference>
  <reference>
    <citation>De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D; Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003 Sep;24(17):1601-10.</citation>
    <PMID>12964575</PMID>
  </reference>
  <reference>
    <citation>Giampaoli S, Capewell S, Shelley E, Allender S, Briggs A, Jorgensen T, Labarthe D, Marques-Vidal P, Stegmayr B, Verschuren WM, Zdrojewski T. Foreword. Eur J Cardiovasc Prev Rehabil. 2007 Dec;14 Suppl 3:S1. doi: 10.1097/01.hjr.0000296928.40040.b0.</citation>
    <PMID>18091132</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2008</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <results_first_submitted>September 29, 2015</results_first_submitted>
  <results_first_submitted_qc>November 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2015</results_first_posted>
  <last_update_submitted>November 12, 2015</last_update_submitted>
  <last_update_submitted_qc>November 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral arterial disease</keyword>
  <keyword>secondary prevention</keyword>
  <keyword>cardiovascular /atherothrombotic events</keyword>
  <keyword>European guidelines</keyword>
  <keyword>Cardiovascular disease prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted by 85 primary care physicians-researchers from Slovenia, acountry with a population of about 2 million. Participating physicians were educated on cardiovascular disease prevention according to the European guidelines attended annual progress report meetings and were visited at least once a year by a study monitor.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Peripheral Arterial Disease</title>
          <description>Subjects with stable peripheral arterial disease; ankle-brachial pressure index on at least one leg =&lt; 0.90.
Implementation of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice .</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Subjects without peripheral arterial disease (palpable pedal pulses and a normal ankle-brachial pressure index of 0.91-1.30), age- and sex-matched to the stuy group with PAD
Implementation of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice .</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="742"/>
                <participants group_id="P2" count="713"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="542"/>
                <participants group_id="P2" count="573"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peripheral Arterial Disease</title>
          <description>Subjects with stable peripheral arterial disease; ankle-brachial pressure index on at least one leg =&lt; 0.90.
Implementation of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice (Eur Heart J 2003; 24: 1601-10, Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1-113).</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Subjects without peripheral arterial disease (palpable pedal pulses and a normal ankle-brachial pressure index of 0.91-1.30), age- and sex-matched to the stuy group with PAD
Implementation of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice (Eur Heart J 2003; 24: 1601-10, Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1-113).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="742"/>
            <count group_id="B2" value="713"/>
            <count group_id="B3" value="1455"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.1" spread="8.8"/>
                    <measurement group_id="B2" value="64.7" spread="9.2"/>
                    <measurement group_id="B3" value="64.9" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="275"/>
                    <measurement group_id="B3" value="552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="465"/>
                    <measurement group_id="B2" value="438"/>
                    <measurement group_id="B3" value="903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Slovenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="742"/>
                    <measurement group_id="B2" value="713"/>
                    <measurement group_id="B3" value="1455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Major Cardiovascular Events</title>
        <description>Total number of deaths, cardiovascular deaths, non-fatal myocardial infarctions, ischemic strokes and critical limb ischemia.</description>
        <time_frame>5 years:</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peripheral Arterial Disease</title>
            <description>Subjects with stable peripheral arterial disease; ankle-brachial pressure index on at least one leg =&lt; 0.90.
Implementation of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice (Eur Heart J 2003; 24: 1601-10, Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1-113).</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects without peripheral arterial disease (palpable pedal pulses and a normal ankle-brachial pressure index of 0.91-1.30), age- and sex-matched to the stuy group with PAD
Implementation of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice (Eur Heart J 2003; 24: 1601-10, Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1-113).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Cardiovascular Events</title>
          <description>Total number of deaths, cardiovascular deaths, non-fatal myocardial infarctions, ischemic strokes and critical limb ischemia.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="742"/>
                <count group_id="O2" value="713"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death of all causes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-fatal myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-fatal ischemic stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Critical limb ischemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Survival, major-event-free survival and event-free survival of patients with PAD and control subjects was estimated by the Kaplan-Meier method and compared by the log-rank test. The numbers of non-fatal events and revascularization procedures (which could be more than one per person) were compared using the Poisson regression – the outcome being the number of events per person-year.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Revascularization Procedures</title>
        <description>Incidence of coronary, carotid and peripheral arterial revascularization procedures</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peripheral Arterial Disease</title>
            <description>Subjects with stable peripheral arterial disease; ankle-brachial pressure index on at least one leg =&lt; 0.90.
Implementation of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice (Eur Heart J 2003; 24: 1601-10, Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1-113).</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects without peripheral arterial disease (palpable pedal pulses and a normal ankle-brachial pressure index of 0.91-1.30), age- and sex-matched to the stuy group with PAD
Implementation of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice (Eur Heart J 2003; 24: 1601-10, Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1-113).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Revascularization Procedures</title>
          <description>Incidence of coronary, carotid and peripheral arterial revascularization procedures</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="742"/>
                <count group_id="O2" value="713"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peripheral arterial revascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coronary revascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>carotid revascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal aortic revascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Death of all causes, non-fatal major ischemic events (myocardial infarction, ischemic stroke, critical limb ischemia) and revascularization procedures were recorded yearly for 5 years.</time_frame>
      <desc>At the time of yearly follow-up, non-fatal major ischemic events and revascularization procedures in the previous year were recorded according to medical records. In case of a &quot;no show&quot; on a scheduled visit, subjects or their relatives and their family physician were actively contacted.</desc>
      <group_list>
        <group group_id="E1">
          <title>Peripheral Arterial Disease</title>
          <description>Subjects with stable peripheral arterial disease; ankle-brachial pressure index on at least one leg =&lt; 0.90.
Implementation of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice (Eur Heart J 2003; 24: 1601-10, Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1-113).</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Subjects without peripheral arterial disease (palpable pedal pulses and a normal ankle-brachial pressure index of 0.91-1.30), age- and sex-matched to the stuy group with PAD
Implementation of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice (Eur Heart J 2003; 24: 1601-10, Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1-113).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="195" subjects_at_risk="742"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Non-fatal myocardial infarction</sub_title>
                <counts group_id="E1" events="50" subjects_affected="50" subjects_at_risk="742"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death of all causes</sub_title>
                <counts group_id="E1" events="112" subjects_affected="112" subjects_at_risk="742"/>
                <counts group_id="E2" events="47" subjects_affected="47" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Non-fatal ischemic stroke</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="742"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Critical limb ischemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="742"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="284" subjects_at_risk="742"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial revascularization procedure</sub_title>
                <description>Endovascular or surgical peripheral arterial revascularization</description>
                <counts group_id="E1" events="183" subjects_affected="183" subjects_at_risk="742"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>Coronary revascularization procedure</sub_title>
                <description>Percutaneous coronary intervention or surgical coronary revascularization</description>
                <counts group_id="E1" events="64" subjects_affected="64" subjects_at_risk="742"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>Carotid revascularization</sub_title>
                <description>Surgical carotid endarterectomy or carotid artery stenting</description>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="742"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="713"/>
              </event>
              <event>
                <sub_title>Abdominal aortic revascularization</sub_title>
                <description>Surgical aortic repair or endovascular aortic repair (EVAR)</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="742"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="713"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ales Blinc, MD, DSc</name_or_title>
      <organization>Department of Vascular Diseases, University of Ljubljana Med Ctr</organization>
      <phone>+386 1 522 80 32</phone>
      <email>ales.blinc@kclj.si</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

